SCHEMBL4192471

SCHEMBL4192471

O=C(Nc1ccc(Cl)cn1)c1cc[nH]n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
RAB9A P51151 11/20 0.57
NPC1 O15118 8/20 0.57
TSHR P16473 5/20 0.57
BRD4 O60885 1/20 0.56
ALOX15 P16050 2/20 0.56
PTK2 Q05397 1/20 0.55
SMN1; SMN2 Q16637 8/20 0.55
TP53 P04637 2/20 0.55
NFKB1 P19838 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
HTT P42858 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 2/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178487 0.85 RAB9A (0.50) RAB9ANPC1SMN1; SMN2TP53KMT2A
SCHEMBL4185825 0.84 GRM5 (0.53) KDM4E
SCHEMBL4194916 0.84 PTGS1 (0.51) L3MBTL1RAB9ANPC1TSHRBRD4
SCHEMBL23246023 0.81 NPC1 (0.53) RAB9ANPC1ALOX15SMN1; SMN2HTT
SCHEMBL4178804 0.80 PTGS1 (0.58) RAB9ANPC1POLB
SCHEMBL4189252 0.78 ALOX15 (0.58) L3MBTL1RAB9ANPC1TSHRBRD4
SCHEMBL1198985 0.77 NPC1 (0.58) L3MBTL1RAB9ANPC1TSHRALOX15
SCHEMBL18172067 0.76 RAB9A (0.62) L3MBTL1RAB9ANPC1TSHRBRD4
SCHEMBL4675605 0.75 RAB9A (0.63) L3MBTL1RAB9ANPC1TSHRBRD4
SCHEMBL6903787 0.75 ALOX15 (0.58) L3MBTL1RAB9ANPC1TSHRBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528792-B2 Sulfonamide compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2026-01-20 US disclosed
US-20240317717-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2024-09-26 US disclosed
EP-4028395-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER Trobio Therapeutics Pty Ltd (AU) 2022-07-20 EP disclosed
WO-2021072487-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2021-04-22 WO disclosed
US-20090143440-A1 Pyrazoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143440-A1 Pyrazoles Useful in the Treatment of Inflammation ALOX15, ALOX12, ALOX15B L3MBTL1 2716/4885RAB9A 3588/4885NPC1 2790/4885
US-20240317717-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER STS, TP53, SQOR L3MBTL1 2561/4885RAB9A 3639/4885NPC1 4336/4885
US-12528792-B2 Sulfonamide compounds and the use thereof in the treatment of cancer SLC10A6, SLCO4C1, SLCO2A1 L3MBTL1 718/4885RAB9A 3784/4885NPC1 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.